Valneva (ADR) (VALN)
Develops, manufactures, and sells travel vaccines alongside infectious-disease vaccine programs.
Something off on this page? Send us feedback.
Commercial products include IXIARO, DUKORAL, and IXCHIQ, alongside vaccine programs for infectious diseases. Formed from the Intercell–Vivalis merger, it combines a travel-vaccine commercial base with vaccine development and manufacturing capabilities.
Develops, manufactures, and commercializes vaccines for infectious diseases. Its commercial portfolio includes IXIARO/JESPECT for Japanese encephalitis, DUKORAL for cholera and, in some markets, ETEC-related diarrhoea, and IXCHIQ; vaccine programs extend beyond travel vaccines.
Formed through the merger of Intercell and Vivalis, the business combines vaccine development and commercialization capabilities with an earlier antibody-discovery heritage. Operations span Austria, Sweden, the UK, France, Canada, and the United States.
Nasdaq ADSs trade alongside Euronext Paris ordinary shares. In the United States, the FDA suspended IXCHIQ's licence, after which the company withdrew its BLA and IND applications and the IND was placed on clinical hold pending an investigation.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Aug 11, 2026 | Cowen & Co. | Initiate | Rating: — | |
| Apr 22, 2026 | Goldman Sachs | Downgrade | ||
| Apr 16, 2026 | Guggenheim | Target | Target: $15 | Target: $11 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $139.0M · Total debt $240.4M · Total assets $444.1M · Shareholders' equity $92.8M
- Revenue
- $40.6M
- Operating income
- −$31.6M
- Net income
- −$36.3M
Reported in EUR, converted at the latest exchange rate
No dividends on record.
| Institutions | 3.99% | 3.78M ADS | |
|---|---|---|---|
| 20 holders · as of Jun 30, 2026 | |||
| Strategic holders | 10.07% | 9.55M ADS | |
| 1 holder · as of Jun 29, 2022 | |||
| Other | 85.94% | 81.49M ADS | |
| remainder | |||
94.82M ADS (1 ADS = 2 ordinary shares) as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
Two share counts disagree (86.77M in the company's Sep 22, 2026 report, 94.82M elsewhere); stakes use the report.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Pfizer Inc.Strategic | 10.07% | 9.55M | filed Jun 29, 2022 |
Frazier Life Sciences Management, L.P.Institution | 2.42% | 2.29M ADS | as of Jun 30, 2026 |
Vivo Capital, LLCInstitution | 0.80% | 763,199 ADS | as of Jun 30, 2026 |
General American Investors Co IncInstitution | 0.37% | 354,361 ADS | as of Jun 30, 2026 |
Millennium Management LLCInstitution | 0.14% | 135,223 ADS | as of Jun 30, 2026 |
Insider tradesForm 4
Nothing filed in the last 12 months.
- Takeda (ADR)
Japanese encephalitis vaccine marketer in Japan
- Sanofi (ADR)
Travel-vaccine portfolio supplier in endemic-region channels
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Valneva (ADR) | $6.60 | −0.38% | $627.7M | — | — | 3.8 | −29.2% |
| Takeda (ADR) | $19.03 | +0.71% | $60.11B | 52.5 | 60.1 | 2.0 | +4.2% |
| Sanofi (ADR) | $42.36 | −0.32% | $102.05B | 75.6 | — | 1.8 | +11.2% |
| Median | 64.1 | 60.1 | 1.9 | +7.7% |